Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Testicular cancer].

Jan Oldenburg1, Gustav Lehne, Sophie D Fosså

  • 1Fagområde Klinisk kreftforskning, Kreftklinikken Radiumhospitalet, Rikshospitalet, 0310 Oslo. jan.oldenburg@medisin.uio.no

Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|February 16, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer.

Future oncology (London, England)·2026
Same author

A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes.

Future oncology (London, England)·2026
Same author

Corrigendum to "Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study" [Eur J Cancer 213 (December) (2024) 115078].

European journal of cancer (Oxford, England : 1990)·2025
Same author

Impact of calcifications on paravalvular leakage by transcatheter aortic valve prostheses: findings from a new in silico clinical trial framework.

Biomechanics and modeling in mechanobiology·2025
Same author

Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.

Lancet (London, England)·2025
Same author

Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.

Lancet (London, England)·2025
Same journal

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same journal

Correction: Management of acute epistaxis.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same journal

A woman in her 70s with chest pain and elevated troponin T levels.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same journal

More systematic follow-up after childbirth.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same journal

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same journal

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
See all related articles

Testicular cancer incidence is rising globally, particularly in Norway and Denmark. Advanced testicular cancer treatment, primarily cisplatin chemotherapy, offers over 80% cure rates and nearly 95% cancer-specific survival.

Area of Science:

  • Oncology
  • Urology

Context:

  • Testicular cancer is the most common cancer in Norwegian men aged 15-40.
  • Incidence has doubled in Norway and Denmark over 50 years, reaching the world's highest rates.

Purpose:

  • To review current management strategies for testicular cancer.
  • To highlight advancements in treatment and their impact on patient outcomes.

Summary:

  • Cisplatin-based chemotherapy, introduced in the early 1980s, has significantly improved survival for advanced testicular cancer.
  • Over 80% of patients achieve cure, with cancer-specific survival approaching 95%, even for those with metastases.
  • Post-orchiectomy treatment is centralized at university hospitals.

Impact:

  • Demonstrates the effectiveness of modern chemotherapy in treating testicular cancer.

Related Experiment Videos

  • Highlights the importance of managing treatment-induced side effects.
  • Provides insights into the successful management of a prevalent cancer in young men.